Results 91 to 100 of about 536 (130)
Characterization of ADME properties of [14C]asunaprevir (BMS-650032) in humans
, 2016 1. Asunaprevir (ASV, BMS-650032), a highly selective and potent NS3 protease inhibitor, is currently under development for the treatment of chronic hepatic C virus infection. This study describes in vivo biotransformation in humans and the identification Hao Jiang (95017), W. Griffith Humphreys (842751), Bing He (135034), Vinod Arora (842748), Ramaswamy A. Iyer (842752), Jiachang Gong (842746), Thomas Philip (842749), John Easter (842750), Timothy Eley (842747), Wenying Li (842753) +9 morecore +1 more sourceDiscovery of a
Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis
C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential
for Once-Daily Dosing
, 2016 The
discovery of a back-up to the hepatitis C virus NS3 protease inhibitor
asunaprevir (2) is described. The objective of this work
was the identification of a drug with antiviral properties and toxicology
parameters similar to 2, but with a preclinical ...Paul Falk (1834291), Maria Donoso (3076479), Brian
L. Venables (3076482), Luciano Mueller (1629796), Paul M. Scola (1639726), Sing-Yuen Sit (1834315), Huabin Sun (136356), Donna M. Bilder (1834252), Yong-Hae Han (1834264), Richard Rampulla (1601455), Jacques Friborg (715566), Anthony Cocuzza (1834261), Kathy Mosure (1834165), Barbara Zheng (1834270), Li-Qiang Sun (1834282), Danshi Li (1834276), Qian Zhao (217607), Alicia Ng (1442749), Herbert E. Klei (486974), Paul
C. Levesque (3076500), Ying-Kai Wang (1834240), Mark
I. Cockett (3076488), Dennis Hernandez (1834255), Hua Fang (627909), Jay O. Knipe (1834321), Kevin Kish (1399378), Amy K. Sheaffer (1834249), Eric Mull (3076497), Ny Sin (1834294), Fei Yu (61577), Richard Schartman (2012938), Lucy Sun (448588), Dennis M. Grasela (1834273), Stephen Adams (1780435), Hong Shi (177669), Pirama
Nayagam Arunachalam (3076485), James Loy (2611882), Fiona McPhee (414636), Qi Gao (133189), Steven Levine (127461), Jeffrey Tredup (2213062), Chaoqun Chen (354923), Arvind Mathur (144120), Tatyana Zvyaga (1834306), Yan Chen (4308), William Warner (3076491), Bang-Chi Chen (1565908), Nicholas A. Meanwell (362044), Theerthagiri Palani (3076476), Michael W. Sinz (1834258), Jialong Zhu (1834288), Jie Chen (5892), Ramkumar Rajamani (1442725), Alan Xiangdong Wang (1834303), Sivakumar Ganesan (3076494), Stanley D’Andrea (1834246) +55 morecore +1 more sourceFixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
, 2015 IMPORTANCE: The antiviral activity of all-oral, ribavirin-free, direct-acting antiviral regimens requires evaluation in patients with chronic hepatitis C virus (HCV) infection.Tse, Edmund, McPhee, Fiona, Hughes, Eric, Poordad, Fred, Sepe, Thomas, Bennett, Michael, Bronowicki, Jean-Pierre, Lee, Samuel S, Sievert, William, Tam, Edward, Levin, James, Conway, Brian, de Lédinghen, Victor, Swenson, E Scott, Jacobson, Ira, Ortiz-Lasanta, Grisell, Yin, Philip D, Boyer, Nathalie, Boparai, Navdeep, Mollison, Lindsay, Bräu, Norbert, Pol, Stanislas, Muir, Andrew J, Reddy, K Rajender, Sulkowski, Mark, Yozviak, Joseph L, DO, FACP, Angus, Peter +26 morecore Estudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud público chileno
, 2017 © 2017 Objectives To assess the impact on the 2015 national health budget of incorporating Daclatasvir/Asunaprevir (DCV / ASV) for the treatment of Hepatitis C genotype 1b (HC1b) in Chile.Vargas, C., Soza, Alejandro, A. Soza, Giglio, A., Espinoza, M. A., Soza, A., Espinoza Sepúlveda, Manuel Antonio, C. Vargas, Espinoza, MA, Vargas, C, Soza, A, A. Giglio, Giglio, A, M.A. Espinoza +13 morecore +1 more sourceSuccesful treatment of chronic hepatitis C virus infection with daclatasvir and asunaprevir in a transfusion dependent thalassaemia patient
, 2016 Thalassaemia is one of the most common inherited hemoglobinopathies that is characterized with defective hemoglobin synthesis and ineffective erythropoiesis. Chronic transfusion therapy which increases the risk of hepatitis C virus (HCV) infection is the ÖZTÜRK, ÖMER, KÖKLÜ, SEYFETTİN, Aksoy, Evrim Kahramanoglu, Tseveldorj, Nomingerel, KÖKLÜ, HAYRETDİN +4 morecore Mixed HCV Infection of Genotype 1B and Other Genotypes Influences Non-response during Daclatasvir + Asunaprevir Combination Therapy
Daclatasvir (DCV) + asunaprevir (ASV) combination therapy has become available for patients with hepatitis C virus (HCV) serogroup 1 infection. We studied the efficacy of this therapy by focusing on the factors associated with sustained virological ...Sakaguchi, Kosaku, Takaguchi, Koichi, Kubota, Junichi, Moriya, Akio, Miyatake, Hirokazu, Okada, Hiroyuki, Yasunaka, Tetsuya, Kawaguchi, Mitsuhiko, Kobashi, Haruhiko, Kariyama, Kazuya, Takayama, Hiroki, Iwasaki, Yoshiaki, Wada, Nozomu, Morimoto, Yoichi, Ikeda, Fusao, Takeuchi, Yasuto, Hashimoto, Noriaki, Hagihara, Hiroaki, Mori, Chizuru, Fujioka, Shin-ichi, Takaki, Akinobu +20 morecore Some of the next articles are maybe not open access.Related searches:
